A long-acting, injectable form of the antipsychotic drug aripiprazole (Abilify, Otsuka) given once a month provides a safe and effective means of maintenance therapy for the treatment of bipolar I ...

Oct. 25, 2005 (Toronto) — Children and adolescents with schizophrenia, bipolar disorder, and other severe psychiatric diagnoses improved significantly when treated with aripiprazole (Abilify) and ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...

TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . Otsuka Pharmaceutical Co. Ltd. and Lundbeck recently announced the FDA approved extended-release injectable ...

The evidence base for the prescribing of aripiprazole in maintenance treatment of bipolar disorder is limited to a single trial, sponsored by the manufacturer of aripiprazole, according to a rigorous ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

Riding strong sales momentum with Abilify Maintena, partners Otsuka and Lundbeck are setting out for a label expansion in the U.S. for their long-acting injectable antipsychotic. If approved, the ...

If approved, aripiprazole 2-month ready-to-use (RTU), long-acting injectable (LAI) would be the first 2-month, LAI antipsychotic indicated for both treatment of schizophrenia and the maintenance ...

The UK’s National Institute for Health and Care Excellence (NICE) has backed the use of Otsuka’s Abilify in teenagers with bipolar disorder. The cost-effectiveness watchdog for the NHS in England and ...

Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, ...